Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This open label randomized controlled multicenter phase II trial will evaluate the clinical impact of the use of HFNC vs. conventional oxygen therapy in patients with moderate and severe hypoxemic acute respiratory failure secondary to SARS-CoV-2 infection.
Description: Need for intubation / support with invasive mechanical ventilation.
Measure: Intubation rate Time: 28 daysDescription: Time to improvement of clinical status according to the 7-point ordinal scale. Modified 7-point ordinal scale: An ordinal scale of 7 points where 1= Ambulatory/no limitation of activities and 7= Death. Low scores denote a better outcome and high scores denote a worse outcome. Time to reduction in scale score will be measured (daily scale scoring).
Measure: Modified 7-point ordinal scale improvement Time: 28 daysDescription: Whether or not each patient required mechanical ventilation during the first 7 days after randomization will be assessed. Proportion of patients with early mechanical ventilation will be calculated for each group.
Measure: Proportion of patients with requirement of early mechanical ventilation. Time: 7 daysDescription: Time until intubation / support with invasive mechanical ventilation
Measure: Intubation time Time: 28 daysDescription: Days off from mechanical ventilation
Measure: Mechanical ventilation (days off) Time: 28 daysDescription: Sequential Organ Failure Assessment (SOFA) score used to track overall organ function and failure. Low scores mean a better outcome, and high scores denote limited organ function and/or organ failure and mean a worse outcome.
Measure: SOFA score over time Time: 14 daysDescription: Sequential Organ Failure Assessment (SOFA) score used to track overall organ function and failure. Low scores denote adequate organ function and mean a better outcome; high scores denote limited organ function and/or organ failure and mean a worse outcome.
Measure: Extra-pulmonary SOFA score over time Time: 7 and 14 daysDescription: Days from randomization to mechanical ventilation initiation, stratified by initial PaO2/FiO2 > and < than 150 mmHg.
Measure: Time free of mechanical ventilation in patients with initial PaO2/FiO2 > and <150 mmHg. Time: 28 daysDescription: Requirement of intubation and mechanical ventilation, stratified by PaO2/FiO2 > and < than 150 mmHg during.
Measure: Frequency of mechanical ventilation in patients with PaO2/FiO2 > and <150 mmHg. Time: 28 daysDescription: Days from randomization to mechanical ventilation initiation, stratified by initial IL6 > and < 100 pg/mL.
Measure: Time free of mechanical ventilation in patients with initial IL6 > and < 100 pg/mL. Time: 28 days.Description: Days from randomization to mechanical ventilation initiation, stratified age > and < 60 years.
Measure: Time free of mechanical ventilation in patients with age > and < 60 years. Time: 28 daysDescription: Requirement of intubation and mechanical ventilation, stratified by age > and < 60 years.
Measure: Frequency of mechanical ventilation in patients with age > and < 60 years. Time: 28 daysDescription: Correlation between days with HFNC and days free of mechanical ventilation in patients who eventually require mechanical ventilation in the HFNC arm.
Measure: High flow nasal canula and time free of mechanical ventilation. Time: 28 daysDescription: Correlation between days with HFNC and severity of multiorgan dysfunction (Sequential Organ Failure Assessment [SOFA] score) , at the time of mechanical ventilation initiation in patients subjected to mechanical ventilation.
Measure: High flow nasal canula and severity of multiorgan dysfunction according to SOFA score. Time: 14 daysDescription: Correlation between HACOR score at 2 and 4 hours post-randomization and days free of mechanical ventilation.
Measure: HACOR relationship to days off from mechanical ventilation. Time: 28 daysDescription: Correlation between HACOR score at 2 and 4 hours post-randomization and multiorganic dysfunction assessed with Sequential Organ Failure Assessment [SOFA] score at day 14 after randomization
Measure: HACOR relationship to multiorganic dysfunction. Time: 14 daysDescription: Correlation between ROX score at 2 and 4 hours post-randomization and days free of mechanical ventilation
Measure: ROX relationship to days off from mechanical ventilation. Time: 28 daysDescription: Correlation between ROX score at 2 and 4 hours post-randomization and multiorganic dysfunction assessed with Sequential Organ Failure Assessment [SOFA] score at day 14 after randomization.
Measure: ROX relationship to multiorganic dysfunction. Time: 14 daysDescription: Differences of increases/reductions between measurements of IL-6 and IL-8 during the first 14 days after randomization. Both IL-6 and IL-8 have the same unit of measure = pg/mL.
Measure: IL-6 and IL-8 levels over time Time: 14 daysDescription: Differences in increases/reduction over time of ferritin measurements between groups.
Measure: Variations in serum ferritin levels. Time: 14 daysDescription: Differences in increases/reduction over time of LDH measurements between groups.
Measure: Variations in serum LDH levels. Time: 14 daysDescription: Differences in increases/reduction over time of leukocyte count measurements between groups.
Measure: Variations in serum leukocyte levels. Time: 14 daysDescription: Differences in increases/reduction over time of neutrophil/lymphocyte count relationship measurements between groups.
Measure: Variations in serum neutrophil/lymphocyte count levels. Time: 14 daysDescription: Differences in increases/reduction over time of platelet count measurements between groups.
Measure: Variations in serum platelet count levels. Time: 14 daysDescription: Differences in increases/reduction over time of D-dimer measurements between groups.
Measure: Variations in serum D-dimer measurements. Time: 14 daysDescription: Days off from renal replacement therapy
Measure: Days off from renal replacement therapy Time: 28 daysDescription: Duration of stay in ICU
Measure: ICU length of stay Time: 28 daysDescription: Duration of hospital stay
Measure: Length of stay in hospital Time: 28 daysDescription: Hospital mortality
Measure: All-cause day-28 mortality Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports